Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

THE CLINICAL TRIAL APPROVAL FOR SIM0709 (TL1A/IL-23P19 BISPECIFIC ANTIBODY) ISSUED BY THE GERMAN REGULATORY AUTHORITY AND ETHICS COMMITTEE

This announcement is made by Simcere Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that SIM0709, a TL1A/IL-23p19 bispecific antibody independently developed by the Group has received approval from Germany's Paul-Ehrlich-Institut (PEI) and the competent German Ethics Committee to initiate a phase 1 clinical trial in healthy participants. SIM0709 is being advanced globally with Boehringer Ingelheim ("**BI**"), and the target indication is inflammatory bowel disease ("**IBD**").

ABOUT SIM0709

SIM0709 is a long-acting humanized bispecific antibody independently using the Group's proprietary multi-specific antibody platform. SIM0709 has been designed to simultaneously target tumor necrosis factor ligand superfamily member 15 (TL1A) and interleukin-23 (IL-23), thereby blocking two core pathways that are implicated in the development and progression of IBD and overcome the efficacy ceiling of current single-target therapies in IBD. In both in vitro primary cell studies and in vivo animal studies, SIM0709 demonstrated superior synergistic efficacy, outperforming the combination of the two corresponding monotherapies.

In January 2026, Simcere Pharmaceutical Co., Ltd. (先聲藥業有限公司) ("**Jiangsu Simcere**"), a subsidiary of the Company, entered into an exclusive licensing agreement (the "**License Agreement**") with BI. Pursuant to the License Agreement, BI would have the exclusive global rights, outside of Greater China, of SIM0709, and the Group is eligible to receive an upfront payment of EUR42 million as well as success-based development, regulatory and sales milestone payments of up to EUR1,016 million. The Group is also eligible for tiered royalties on net sales outside Greater China.

ABOUT THE GROUP

The Company is an innovation and R&D-driven pharmaceutical company and the Group has established a "State Key Laboratory of Neurology and Oncology Drug Development". The Group focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of "for patients, for life". Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, November 9, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. TANG Renhong as the non-executive Director; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.